Brief: Arch Biopartners Announces Start Of Phase I Human Trial For Metablok
19/06/2019 12:41
June 19 (Reuters) - Arch Biopartners Inc ARCH.V :
* ARCH BIOPARTNERS ANNOUNCES START OF PHASE I HUMAN TRIAL
FOR
METABLOK
* ARCH BIOPARTNERS INC - FORTY-FOUR PARTICIPANTS ARE
SCHEDULED TO
BE ENROLLED IN TRIAL OVER NEXT FEW MONTHS.
Source text for Eikon: ID:nGNXbY37k7
Further company coverage: ARCH.V
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Arch Biopartners
See all newsBrief: Arch Biopartners To Expand Phase Ii Cardiac Surgery-Associated Acute Kidney Injury Trial To The US
Brief: Arch Biopartners Closes Non-Brokered Private Placement
Brief: Arch Strengthens Its Position As A Leading Kidney Therapeutics Company With The Acquisition Of A Breakthrough Platform To Develop New Drugs Targeting Chronic Kidney Disease (Ckd)
Brief: Arch Biopartners Closes Non-Brokered Private Placement
Brief: Arch Biopartners Announces Ontario Research Ethics Board Approval To Start Phase II Trial For LSALT Peptide